Eledon posts Q4 net loss $9.6M, highlights Phase 2 BESTOW enrollment and xenotransplant use

Eledon Pharmaceuticals, Inc.

Net loss of $9.6M ($0.32/shr) for Q4 2023; full year net loss $40.3M ($1.64/shr).
Cash and equivalents $51.1M as of Dec 31, 2023; down from $56.4M year-end 2022.
12 participants enrolled in Phase 2 BESTOW trial of tegoprubart vs tacrolimus in kidney transplant.
Phase 1b data (n=11) showed tegoprubart safe, with eGFR >70 mL/min at all post-90-day time points.
Tegoprubart used in first pig-to-human kidney xenotransplant on March 16, 2024 at Massachusetts General Hospital.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Eledon Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income net loss of $40.3 million, or $1.64 per share, EPS $1.64 per share.

Period: the year ended December 31, 2023
Net income: net loss of $40.3 million, or $1.64 per share
EPS: $1.64 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $40.3 million, or $1.64 per share, for the year ended December 31, 2023, compared to a net loss of $88.0 million, or $6.16 per share, in 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Eledon Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income net loss of $9.6 million, or $0.32 per share, EPS $0.32 per share.

Period: the three months ended December 31, 2023
Net income: net loss of $9.6 million, or $0.32 per share
EPS: $0.32 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $9.6 million, or $0.32 per share, for the three months ended December 31, 2023, compared to a net loss of $58.4 million, or $4.09 per share, for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-038008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.